Gilead Sciences Inc (GILD): Next-Year EPS Estimate 16229.26%
As of 2026-06-04, Gilead Sciences Inc (GILD) has a next-year EPS growth estimate of 16229.26%.
On 2026-06-03, analyst consensus for GILD's next-year EPS growth shifted from 3575.07% to 16229.26% — a positive change of 12654.19 percentage points. The revised estimate has been sustained across 2 subsequent trading sessions. Current-year growth is projected at -100.73%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- EPS growth next year
- 16229.26%
- EPS growth this year
- -100.73%
- EPS next quarter (est)
- -$6.59
- Last price
- $129.18
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 16229.26% | -100.73% | -$6.59 | $129.18 |
| 2026-06-03 | 16229.26% | -100.73% | -$6.59 | $128.99 |
| 2026-06-02 | 3575.07% | -96.79% | -$6.59 | $127.57 |
| 2026-06-01 | 3575.07% | -96.79% | -$6.59 | $131.10 |
| 2026-05-31 | 3577.44% | -96.79% | -$6.59 | $134.43 |
| 2026-05-28 | 3577.44% | -96.79% | -$6.59 | $136.22 |
| 2026-05-27 | 3577.44% | -96.79% | -$6.59 | $133.69 |
| 2026-05-26 | 3577.44% | -96.79% | -$6.59 | $133.73 |
| 2026-05-25 | 3577.44% | -96.79% | -$6.59 | $134.36 |
| 2026-05-24 | 3577.44% | -96.79% | -$6.59 | $134.36 |
| 2026-05-21 | 3577.44% | -96.79% | -$6.59 | $130.50 |
| 2026-05-20 | 3577.44% | -96.79% | -$6.59 | $130.69 |
| 2026-05-19 | 1479.03% | -92.52% | -$6.60 | $130.50 |
| 2026-05-18 | 1479.03% | -92.52% | -$6.60 | $129.67 |
| 2026-05-17 | 902.92% | -88.23% | -$6.60 | $129.58 |
| 2026-05-14 | 631.95% | -83.83% | -$6.60 | $132.06 |
| 2026-05-13 | 631.95% | -83.83% | -$6.60 | $133.04 |
| 2026-05-12 | 479.94% | -79.58% | -$6.89 | $134.94 |
| 2026-05-11 | 479.88% | -79.58% | -$6.85 | $133.52 |
| 2026-05-10 | 308.65% | -70.91% | -$7.03 | $131.33 |
Recent News
- Here's how much Moderna's stock has rallied off renewed focus on hantavirus researchMarketWatch
- Gilead posts positive Q1 buoyed by HIV drug growthPharmaceutical Technology
- Gilead Earnings Show HIV Drugs Continue to Shine. Why the Guidance Cut?Barrons.com
- Gilead Sciences Expects Loss This Year on Acquired R&D ExpensesThe Wall Street Journal
- Gilead: Q1 Earnings SnapshotAssociated Press
- Gilead Tumbles On Mixed Guidance Update Amid Recent M&A FrenzyInvestor's Business Daily
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Gilead Sciences Inc's next-year EPS growth estimate?▾
As of 2026-06-04, Gilead Sciences Inc (GILD) has a next-year EPS growth estimate of 16229.26%, based on analyst consensus.
When was the latest EPS estimate revision for GILD?▾
The most recent revision occurred on 2026-06-03, when analysts adjusted the next-year EPS growth estimate from 3575.07% to 16229.26%.
What sector and industry does Gilead Sciences Inc belong to?▾
Gilead Sciences Inc operates in the Healthcare sector, specifically the Drug Manufacturers - General industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. GILD appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Gilead Sciences Inc (GILD) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports